



**World Health
Organization**

REGIONAL OFFICE FOR

Europe



**By: Luigi Gradoni
Rogelio López-Vélez
Mourad Mokni**

Manual on case management and surveillance of the leishmaniases in the WHO European Region

**MANUAL ON CASE MANAGEMENT
AND SURVEILLANCE OF THE LEISHMANIASES
IN THE WHO EUROPEAN REGION**

ABSTRACT

This manual makes recommendations on a standardized approach to the case management and epidemiological surveillance of the leishmaniases across the WHO European Region. It was conceived as a practical guide for health workers dealing with the difficult task of diagnosing and treating different clinical forms of leishmaniasis, and for public health workers involved in surveillance systems for infectious diseases. Stepwise decision algorithms are presented for clinical and laboratory diagnosis, as well as for the treatment of various leishmaniasis entities endemic or frequently imported in the Region. The manual provides case and treatment outcome definitions for epidemiological surveillance. Particular attention is given to establishing monitoring and evaluation systems that provide sets of indicators allowing the performance of leishmaniasis control strategies to be properly assessed. Annexes include epidemiological information, antileishmanial drug information, and detailed standard operating procedures for diagnosis and treatment.

KEYWORDS

Leishmaniasis - diagnosis	Leishmaniasis, Cutaneous - prevention and control
Leishmaniasis - epidemiology	Leishmaniasis, Visceral - diagnosis
Leishmaniasis - parasitology	Leishmaniasis, Visceral - epidemiology
Leishmaniasis - prevention and control	Leishmaniasis, Visceral - parasitology
Leishmaniasis, Cutaneous - diagnosis	Leishmaniasis, Visceral - prevention and control
Leishmaniasis, Cutaneous - epidemiology	Europe
Leishmaniasis, Cutaneous - parasitology	

ISBN 978 92 89052 51 1

Address requests about publications of the WHO Regional Office for Europe to:

Publications
WHO Regional Office for Europe
UN City, Marmorvej 51
DK-2100 Copenhagen Ø, Denmark

Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office website (<http://www.euro.who.int/pubrequest>).

© World Health Organization 2017

All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The views expressed by authors, editors, or expert groups do not necessarily represent the decisions or the stated policy of the World Health Organization.

Contents

Acknowledgements.....	iv
Contributors	v
Abbreviations	vi
1. Introduction.....	1
2. The leishmaniasis in the WHO European Region.....	2
2.1 Epidemiology and geographical distribution	2
2.2 VL burden.....	2
2.3 CL burden.....	5
3. Case management of the leishmaniasis in the WHO European Region.....	7
3.1 Case management of VL	7
3.2 Case management of VL in HIV-coinfected patients	15
3.3 Case management of VL in other special categories of patients.....	21
3.4 Case management of CL	23
3.5 Case management of CL in special categories of patients	31
3.6 Imported cases of CL and MCL	32
4. Surveillance.....	33
4.1 General purpose and components.....	33
4.2 Recommended case and treatment outcome definitions for epidemiological surveillance.....	34
4.3 Leishmaniasis case detection strategies	35
4.4 Strategies for the detection of leishmaniasis in the canine reservoir	36
4.5 Recommended types of surveillance.....	37
5. Monitoring and evaluation of leishmaniasis control.....	40
5.1 Leishmaniasis control strategies.....	40
5.2 Indicators for monitoring and evaluation of leishmaniasis control.....	42
Bibliography	45
Annex 1. Country information and annual VL incidence	48
Annex 2. Information on drugs used for treating VL	51
Annex 3. Standard operating procedure for conventional parasitological diagnosis	55
Annex 4. Standard operating procedure for cryotherapy and intralesional injection of antimony.....	57
Annex 5. Standard operating procedure for thermotherapy	59
Annex 6. Systemic treatment of CL with pentavalent antimonials	60
Annex 7. Drug options for imported CL and MCL cases.....	62

Acknowledgements

The World Health Organization would like to thank all the experts who provided input to this manual through participation in the Expert Group Meeting on Finalization of the WHO Regional Manual on Surveillance and Case Management of Leishmaniasis, which was held on 19–21 September 2016 in Tirana, Albania.

The WHO Regional Office for Europe also thanks all country representatives and experts who provided input to the manual through their participation at the regional meeting on surveillance and control of leishmaniasis in the WHO European Region, held in Sofia, Bulgaria, on 10–12 April 2017.

All figures and photographs in this manual are used with the kind permission of Dr Luigi Gradoni of Istituto Superiore di Sanità, Rome; Professor Rogelio López-Vélez of Ramon y Cajal University Hospital, Madrid; Professor Mourad Mokni of La Rabta Hospital, Tunis, and of Tunis El Manar University; and the Oxford University Press/on behalf of Infectious Diseases Society of America.

Contributors

Authors

Luigi Gradoni, Research Director, Unit of Vector-borne Diseases and International Health, Istituto Superiore di Sanità, Rome, Italy

Rogelio López-Vélez, Associate Professor, National Referral Unit for Tropical Diseases, Infectious Diseases Department, Ramon y Cajal University Hospital, Madrid, Spain

Mourad Mokni, Professor, Faculty of Medicine, El Manar University, Tunis, and Head of Department of Dermatology and Research Unit, La Rabta Hospital, Tunis, Tunisia

External peer reviewers

Johannes Blum, Swiss Tropical and Public Health Institute and University of Basel, Basel, Switzerland

Pierre Buffet, National Institute for Blood Transfusion, Faculty of Medicine, Université Paris Descartes, Paris, France

Charles L. Jaffe, National Center for Leishmaniasis, Kuvim Center for Study of Tropical and Infectious Diseases, Hebrew University-Hadassah Medical School, Jerusalem, Israel

Nora Kokaia, Institute of Medical Parasitology and Tropical Medicine, S. Virsaladze, Tbilisi, Georgia

Javier Moreno Nuncio, Unit for Leishmaniasis and Chagas Disease, WHO Collaborating Centre for Leishmaniasis, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

WHO representatives

Elkhan Gasimov, Technical Officer, Malaria and Other Vector-borne and Parasitic Diseases, WHO Regional Office for Europe, Copenhagen, Denmark

José Antonio Ruiz Postigo, Leishmaniasis Control Programme, Department of Neglected Tropical Diseases, WHO headquarters, Geneva, Switzerland

Daniel Argaw Dagne, Coordinator, Innovative and Intensified Disease Management, Department of Neglected Tropical Diseases, WHO headquarters, Geneva, Switzerland

Abbreviations

ABD	amphotericin B deoxycholate	MCL	mucocutaneous leishmaniasis
ABLC	amphotericin B lipid complex	ML	mucosal leishmaniasis
ACD	active case detection	N	number (of patients)
ART	antiretroviral therapy	NGO	nongovernmental organization
BUN	blood urea nitrogen	PAHO	Pan American Health Organization
CBC	complete blood count	PCD	passive case detection
CL	cutaneous leishmaniasis	PCR	polymerase chain reaction
Dx	diagnosis	qPCR	quantitative polymerase chain reaction
ECG	electrocardiogram	RDT	rapid diagnostic test
ELISA	enzyme-linked immunosorbent assay	SAE	serious adverse event
IFAT	immunofluorescence antibody test	Sb⁵⁺	pentavalent antimony
IM	intramuscular	SLA	soluble <i>Leishmania</i> antigens
IV	intravenous	SSG	sodium stibogluconate
LAB	liposomal amphotericin B	TOC	test of cure
LCL	localized cutaneous leishmaniasis	VL	visceral leishmaniasis
MA	meglumine antimoniate		

1. Introduction

Leishmaniasis is a protozoan disease caused by members of the genus *Leishmania*, parasites that infect numerous mammal species including humans, and transmitted by the bite of phlebotomine sandflies. Clinical manifestations of human leishmaniasis, caused by some 20 *Leishmania* species, are largely diverse and can be grouped into two main clinical forms: visceral leishmaniasis (VL), a severe condition that results from the dissemination of *Leishmania* in the phagocytes, mainly macrophages, and which is fatal in almost all cases if left untreated; and cutaneous leishmaniasis (CL), a benign but often disfiguring condition that is caused by the multiplication of *Leishmania* in the phagocytes of the skin and which has a tendency towards spontaneous resolution. The coexistence of these clinical forms in the same patient is rare.

Leishmaniasis are endemic in over 98 countries, with more than 350 million people at risk. It is estimated that 1.3 million new cases of leishmaniasis (0.3 million VL and 1 million CL) occur every year. Like other neglected tropical diseases, leishmaniasis has the characteristics that it is not recognized and prioritized politically, and its visibility is not proportionate to its burden; that national strategies for its control are lacking; and that accurate information on its extent and distribution is often missing. Although estimated to cause the ninth largest disease burden among infectious diseases, leishmaniasis is largely ignored because of its complex epidemiology and ecology, lack of practical tools for its case management, and the inadequacy of current surveillance systems.

Systematic collection and analysis of data associated with leishmaniasis occurrence in populations are necessary for planning, implementation and evaluation of public health practice. Among other things, surveillance data are essential to determine disease trends over time (incidence) and space (spread) in endemic countries; to monitor disease importation into non-endemic countries; to identify boundaries of autochthonous transmission within territories; to detect epidemic clusters; and to monitor and evaluate efforts towards appropriate case management and control.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26332

